Research programme: hepatitis B virus therapeutics - Innocell/Pro-Bion
Latest Information Update: 26 Jan 2011
At a glance
- Originator Innocell Corporation; Pro-Bion
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 26 Jan 2011 Discontinued - Preclinical for Hepatitis B in South Korea (unspecified route)